Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Zuzana Počíková"'
Publikováno v:
BMC Neurology, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Fingolimod, an oral sphingosine 1-phosphate receptor immunomodulator, is approved in Europe for people with multiple sclerosis (pwMS) with highly active disease despite a full and adequate course of treatment with ≥ 1 disease-mo
Externí odkaz:
https://doaj.org/article/7a169674f81b4458af29eae8eeeb00f1
Autor:
Filip Dostal, Jiri Klimes, Zuzana Počíková, Jolana Markova, Adam Svobodník, David Dolezil, Radka Stepanova
Publikováno v:
Journal of Pain Research. 13:2895-2906
Purpose A national primary and secondary healthcare-level study in the Czech Republic has not yet been conducted to evaluate the prevalence of migraine. We analyzed the current treatment patterns (acute and prophylactic) in migraine patients and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58d12c7930ea63fa069dcab29b7f45a9
https://doi.org/10.2147/jpr.s273119
https://doi.org/10.2147/jpr.s273119
Background: Fingolimod, an oral sphingosine 1-phosphate receptor immunomodulator, is approved in Europe for multiple sclerosis (MS) patients with highly active disease despite a full and adequate course of treatment with ≥1 disease-modifying therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::894f7070baa8374389728571b319f92e
https://doi.org/10.21203/rs.3.rs-1007907/v1
https://doi.org/10.21203/rs.3.rs-1007907/v1
Publikováno v:
Clinical Drug Investigation
Background and Objective Once-daily oral fingolimod is approved in the EU as escalation treatment for adult patients with highly active relapsing multiple sclerosis (MS). The efficacy and safety profiles of fingolimod have been well established in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b24a2e9e669a2ee162acbe0785fcdd3f
https://doi.org/10.1007/s40261-016-0471-2
https://doi.org/10.1007/s40261-016-0471-2